This first evidence synthesis for TKI therapy after allogeneic stem-cell transplantation in FLT3-ITD mutated AML found TKI therapy using midostaurin or sorafenib in comparison with control was significantly associated with better outcome in relapse and relapse-free survival. Here, FLT3 is linked to acute myeloid leukemia.